← Back to dashboard
Share
1100%
r/stocks
$ENTX - Entera Receives Positive FDA Feedback on Phase 3 Study for First Oral Anabolic Tablet in Development for Osteoporosis (NASDAQ: ENTX)
Investor summaryBullish
Entera Bio receives positive FDA feedback on its Phase 3 study for an oral anabolic tablet for osteoporosis.
Bull points
- Positive FDA feedback on the Phase 3 study.
- Developing the first oral anabolic tablet for osteoporosis.
This is a link post with no body text.View link ↗
Discussion · top comments
No comment snapshot fetched for this post yet.